Drug Trial Radar · NCT06695117
Study of a Combination Vaccine Comprised of Different Recombinant Spike Antigen Levels of a Matrix-M Adjuvanted Recombinant COVID-19 Vaccine and High-Dose Inactivated Influenza Vaccine in Adult Participants 50 Years of Age and Older
Last checked: Nov 19, 2026Latest source record: May 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
980
Actual
Start
Nov 19, 2024
Primary completion
Apr 16, 2026
Study completion Apr 16, 2026
Sponsor
- Lead sponsor
- SanofiSanofi (SNY)
- Sponsor type
- Industry
- First posted
- Nov 19, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Prevention
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 50 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
Study VBT00001 is planned to be a Phase 1/2, randomized, modified double-blind, active-controlled, multi-center study to be conducted in approximately 980 adults aged 50 years and older in the United States. The purpose of the study is to assess the safety and immunogenicity of IIV-HD (high-dose inactivated influenza vaccine) + rC19 (adjuvanted recombinant COVID-19 vaccine) vaccine comprised of IIV-HD combined with different recombinant Spike (rS) antigen levels of rC19 compared to IIV-HD alone, rC19 (dose 1) alone, and IIV-HD and rC19 (dose 1) (coadministered in opposite arms). Placebo will be coadministered in the IIV-HD alone, rC19 (dose 1) alone, and IIV-HD + rC19 study groups to control for the number of injections and to maintain observer-blinding. Thus, each participant will receive two injections at enrollment, one in each deltoid muscle. Study details include: * The study duration will be approximately 12 months * Study intervention will be administered via a single intramuscular (IM) injection into the right and left deltoid muscles on D01 * Dose escalation with sequential enrollment (sentinel cohort followed by main cohort for a given dose) * The visit frequency will be D01, D09 (telephone call), D30, D182 (telephone call), and D366 (telephone call) Number of Participants: Approximately 980 participants are expected to be randomized.
Conditions
- COVID-19 Immunization
- Influenza Immunization
Interventions
IIV-HDBiological
Inactivated, split-virion
rC19 (dose 1)Biological
Protein subunit
IIV-HD + rC19 (dose 1)Biological
IIV-HD component: Inactivated, split-virion rC19 component: Protein subunit
IIV-HD + rC19 (dose 2)Biological
IIV-HD component: Inactivated, split-virion rC19 component: Protein subunit
IIV-HD + rC19 (dose 3)Biological
IIV-HD component: Inactivated, split-virion rC19 component: Protein subunit
IIV-HD + rC19 (dose 4)Biological
IIV-HD component: Inactivated, split-virion rC19 component: Protein subunit
Placebo (0.9% NaCl)Other
Normal saline
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants with immediate adverse events (AEs)Time frame: Within 30 minutes after each vaccination
- Number of participants with solicited injection site reactionsTime frame: Up to 7 each days after vaccination
- Number of participants with solicited systemic reactionsTime frame: Up to 7 days after each vaccination
- Number of participants with unsolicited AEsTime frame: Up to 28 days after each vaccination
- Number of participants with adverse events of special interest (AESIs)Time frame: Up to 180 days after each vaccination
- Number of participants with medical attended adverse events (MAAEs)Time frame: Up to 180 days after each vaccination
- Number of MAAEs relating to predefined potential immune-mediated disease (PIMDs)Time frame: From D182 through 12 months following the last study vaccination
- Number of participants with serious adverse events (SAEs)Time frame: Up to 180 days after each vaccination
- Number of participants with related SAEsTime frame: From D182 through 12 months following the last study vaccination
- Number of MAAEs relating to predefined PIMDs that meet the criteria for SAEsTime frame: From D182 through 12 months following the last study vaccination
- Geometric mean (GM) of HAI titers in all participantsTime frame: At D01 and D30
- Geometric mean ratio (GMR) HAI titers ratio D30/D01 in all participantsTime frame: At D01 and D30
- GM of SARS-CoV-2 neutralizing titers in all participantsTime frame: At D01 and D30
- GMR of SARS-CoV-2 neutralizing titers ratio D30/D01 in all participantsTime frame: At D01 and D30
Locations
12 sites in 1 country. Site status is shown where the registry gives one.
Simon Williamson Clinic - Birmingham- Site Number : 8400003
Birmingham, Alabama
AES - DRS - Optimal Research Alabama - Huntsville Site Number : 8400006
Huntsville, Alabama
Orange Grove Family Practice- Site Number : 8400012
Tucson, Arizona
Synexus Clinical Research US - The Villages- Site Number : 8400011
The Villages, Florida
Synexus Clinical Research US - Atlanta- Site Number : 8400001
Atlanta, Georgia
Synexus Clinical Research- Site Number : 8400004
Chicago, Illinois
Synexus Clinical Research - St. Louis- Site Number : 8400010
Creve Coeur, Missouri
Synexus Clinical Research - New York- Site Number : 8400007
New York, New York
Optimal Research - Texas- Site Number : 8400002
Austin, Texas
Synexus Clinical Research US - Dallas- Site Number : 8400005
Dallas, Texas
Synexus Clinical Research US - San Antonio- Site Number : 8400009
San Antonio, Texas
Synexus Salt Lake City Site Number : 8400008
Salt Lake City, Utah
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.